Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
Clinical trial NCT06112340 · RECRUITING
Trial details
- NCT number
- NCT06112340
- Sponsor
- Sling Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-11
- Primary completion
- 2026-06-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.